Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? - Authors' reply
- PMID: 34774142
- DOI: 10.1016/S0140-6736(21)02317-5
Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? - Authors' reply
Conflict of interest statement
All authors are employees of AstraZeneca and might have stock, or options, or both. This Correspondence was developed by Steve Hill of Ashfield MedComms, an Ashfield Health company, under the direction and guidance of the authors and with funding support from AstraZeneca.
Comment on
-
Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?Lancet. 2021 Nov 13;398(10313):1801. doi: 10.1016/S0140-6736(21)02285-6. Lancet. 2021. PMID: 34774143 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical